Subgroup Analyses of EMPOWER-LUNG 1

Patients using steroids, especially at high-doses, before taking immune checkpoint inhibitors for non–small cell lung cancer were more likely to have brain metastases.

The investigational agent, zipalertinib, received the breakthrough designation from the FDA in January 2022

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

When small-cell lung cancer (SCLC) has spread to distant parts of the body, it’s classified as extensive-stage, which applies to nearly two-thirds of SCLC cases at the time of diagnosis.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung cancer biomarker subtypes.

Ibtrozi had a 90% response rate in treatment naïve adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, according to the results of a news release.